CMTx Biotech, Inc.

CMTx Biotech, Inc.CMTx Biotech, Inc.CMTx Biotech, Inc.

CMTx Biotech, Inc.

CMTx Biotech, Inc.CMTx Biotech, Inc.CMTx Biotech, Inc.
More

Clinical Stage, SMALL MOLECULE Treatments for Rare & Pandemic Diseases

Clinical Stage, SMALL MOLECULE Treatments for Rare & Pandemic DiseasesClinical Stage, SMALL MOLECULE Treatments for Rare & Pandemic DiseasesClinical Stage, SMALL MOLECULE Treatments for Rare & Pandemic Diseases

Proven Safety | Clinical Stage | Accelerated Development

Contact Us

Clinical Stage, SMALL MOLECULE Treatments for Rare & Pandemic Diseases

Clinical Stage, SMALL MOLECULE Treatments for Rare & Pandemic DiseasesClinical Stage, SMALL MOLECULE Treatments for Rare & Pandemic DiseasesClinical Stage, SMALL MOLECULE Treatments for Rare & Pandemic Diseases

Proven Safety | Clinical Stage | Accelerated Development

Contact Us

About Us

Our Technology

Experienced Management

Development Pipeline

CMTx Biotech is commercializing proprietary small-molecules for the treatment of rare, orphan diseases to improve critical patient outcomes

Development Pipeline

Experienced Management

Development Pipeline

Our lead drug candidate has completed IND-enabling studies and has been tested safely in humans in variety other indications, dramatically accelerating our path to human clinical trials and market approval.

Experienced Management

Experienced Management

Experienced Management

Our management and advisory team is composed of a seasoned group of scientists, business managers, technology commercialization and licensing experts that have multiple  successes in both drug development and commercialization as well as licensing and technology transfer.

Management Team & founders

Profile

Joseph Scaduto, MS, MBA

Lorne Golub, DMD, MSc, MD (Honorary)

Lorne Golub, DMD, MSc, MD (Honorary)

Co-Founder & Chief Executive Officer

image509

Lorne Golub, DMD, MSc, MD (Honorary)

Lorne Golub, DMD, MSc, MD (Honorary)

Lorne Golub, DMD, MSc, MD (Honorary)

Scientific Co-Founder

image510

James Keane, BS, MBA

Lorne Golub, DMD, MSc, MD (Honorary)

Christopher Czura, PhD

Co-Founder & Chief Operating Officer

image511

Christopher Czura, PhD

Christopher Czura, PhD

Christopher Czura, PhD

VP Scientific Affairs

image512

JoAnn Wilson, PhD

Christopher Czura, PhD

JoAnn Wilson, PhD

VP Chemistry, Manufacturing and Controls

image513

Janet S Lee, PhD

Christopher Czura, PhD

JoAnn Wilson, PhD

VP, Clinical Research

image514

Carlos Velez, PhD, MBA

Ashley Holub, MA ,PhD (c)

Ashley Holub, MA ,PhD (c)

VP Business Development

image515

Ashley Holub, MA ,PhD (c)

Ashley Holub, MA ,PhD (c)

Ashley Holub, MA ,PhD (c)

Director, Clinical Research

image516

Sonny Granger

Ashley Holub, MA ,PhD (c)

Sonny Granger

Co-Founder & Charcot-Marie-Tooth Disease Patient Advocate

Scientific, Clinical, and Strategic Advisors

image517

Sharon Nachman, MD

Sharon Nachman, MD

Sharon Nachman, MD

Associate Dean of Research

Stony Brook University School of Medicine

image518

Hani Aiash, MD/PhD

Sharon Nachman, MD

Sharon Nachman, MD

Clinical Assistant Professor

SUNY Upstate Medical University

image519

Andrew Protter

Sharon Nachman, MD

Andrew Protter

Chief Scientific Officer

Auransa, Inc.

Advisor

Peter Young

Michelle Rudek (Renaut)

Andrew Protter

Venture Partner

Pappas Capital

image520

Michelle Rudek (Renaut)

Michelle Rudek (Renaut)

Michelle Rudek (Renaut)

Professor of Oncology and Medicine (Clinical Pharmacology) at Johns Hopkins University

image521

Jay Steinberg, DO

Michelle Rudek (Renaut)

Michelle Rudek (Renaut)

Director of Thoracic Surgery

Jefferson Health New Jersey

image522

Rober Levy, MD

Rober Levy, MD

Rober Levy, MD

CoFounder

PromptCareMD

image523

Daniel Keene

Rober Levy, MD

Rober Levy, MD

Director, Patient Services Innovation, Novartis

Subscribe

Find Us Online

Contact Us

Send Message

Please contact us 

CMTx Biotech, Inc.

Stony Brook, NY

info@cmtxbiotech.com (631) 258-5680

Articles & Publications

CMTx Biotech successfully submitted a Clinical Trial Planning grant application to the National Center for Advancing Translational Sciences (NCATS) this week requesting financial support to design a Phase II clinical study evaluating the safety and efficacy of the company’s lead drug candidate, incyclinide (CMT-3 / COL-3), in hospitalized COVID-19 patients. The company also proposed to engage the U.S. Food and Drug Administration (FDA) in a pre-IND meeting, as well as to prepare and submit an Investigational New Drug (IND) application. Special thanks to our clinical collaborators, Dr. Sharon nachman (Stony Brook University) and Dr. Hani Aiash (SUNY Upstate Medical University), as well as Chris Czura, PhD, Jo Ann Zbur Wilson, Janet S Lee, PhD, Ashley Holub, Daniel Keene, James Keane, MBA, Joseph Scaduto and Andy Protter for their contributions to the written proposal.

https://lnkd.in/d8AKsHS

CMTx Clinical Trial Planning Grant Specific Aims_20_06-18 (pdf)Download

Copyright © 2020 CMTx Biotech, Inc. - All Rights Reserved.


Powered by Airfoil Corp